Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

POINT invests in alpha-emitting Isotope maker

POINT Biopharma Global (NASDAQ:PNT) and IONETIX are collaborating to create Ionetix Alpha Corp., a new subsidiary of IONETIX, to focus on near-term, commercial-scale production of GMP-grade therapeutic isotopes, such as...

May 15, 2023

Developments

Last patient treated in Bellerophon Phase 3 trial in fibrotic lung disease

The last patient has completed blinded treatment in Bellerophon Therapeutics’ (NASDAQ:BLPH) Phase 3 REBUILD study of INOpulse, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic...

May 11, 2023

Markets

BTIG cuts Babylon Health on earnings, cash, go-private transaction

BTIG downgraded Babylon Health (NASDAQ:BBLN) to “sell” from “neutral” with a price target of zero, reflecting concerns around earnings, cash flow and cash needs, and the structure of a possible go-private transaction...

May 11, 2023

Markets

BTIG cuts CareDx to hold on CMS policy changes; removal of guidance

BTIG downgraded CareDx (NASDAQ:CDNA) to “neutral” from “buy” and removed its price target. The stock closed at $8.59 on May 10. CareDx is a market leader in blood-based testing for both heart and kidney transplant...

May 11, 2023

Markets

Research Capital bullish on Theralase bladder cancer data

Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) data generated to date shows that Ruvidar’s efficacy is “strong and durable” for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and...

May 10, 2023

Developments

Review committee recommends Addex continue epilepsy study

An independent interim review committee (IRC), following review of unblinded data from Part 1 of patient Cohort 1, recommended Addex Therapeutics (SIX, NASDAQ:ADXN) continue with the ADX71149 Phase 2 epilepsy clinical...

May 10, 2023

Developments

Sweden Orphan Biovitrium to acquire CTI BioPharma

Sweden Orphan Biovitrium (STO:SOBI) entered into a definitive agreement to acquire CTI BioPharma (NASDAQ:CTIC) for $9.10 a share in cash, representing an implied equity value of approximately $1.7-billion. The...

May 10, 2023

Developments

Theralase updates Phase 2 bladder cancer study

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) updated recently reported interim clinical data from a Phase 2 clinical study of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle Invasive Bladder...

May 10, 2023

Developments

Omeq Medical receives FDA approval for epidural injections smart device

Closely-held Omeq Medical, a portfolio company of Israel’s The Trendlines Group (SGX:42T;TCQX:TRNLY), received regulatory clearance from the FDA for its EpiFinder device, which assists physicians to accurately position...

May 9, 2023

Developments

Acasti submits Phase 3 safety protocol; implements strategic realignment

Acasti Pharma (NASDAQ:ACST) submitted to the FDA the full protocol of its GTX-104 for a Phase 3 safety study of a rare disease, aneurysmal subarachnoid hemorrhage, and implementation of a strategic realignment plan to...

May 8, 2023

Developments

Visus posts positive Phase 3 results in presbyopia

Visus Therapeutics reported that the BRIO-I Phase 3 clinical trial met its primary and secondary endpoints, evaluating the safety and efficacy of BRIMOCHOL PF, a preservative-free ophthalmic solution for the treatment...

May 5, 2023

Developments

FibroGen flunks Phase 3 anemia study

FibroGen’s (NASDAQ:FGEN) Phase 3 MATTERHORN study of roxadustat for treatment of anemia in patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint. The...

May 5, 2023

POINT invests in alpha-emitting Isotope maker

Last patient treated in Bellerophon Phase 3 trial in fibrotic lung disease

BTIG cuts Babylon Health on earnings, cash, go-private transaction

BTIG cuts CareDx to hold on CMS policy changes; removal of guidance

Research Capital bullish on Theralase bladder cancer data

Review committee recommends Addex continue epilepsy study

Sweden Orphan Biovitrium to acquire CTI BioPharma

Theralase updates Phase 2 bladder cancer study

Omeq Medical receives FDA approval for epidural injections smart device

Acasti submits Phase 3 safety protocol; implements strategic realignment

Visus posts positive Phase 3 results in presbyopia

FibroGen flunks Phase 3 anemia study

General

More